44 minutes ago
This analysis evaluated the frequency of peanut-sensitized infants and toddlers being sensitized to other types of nuts.
2 hours ago
Stephen J. Nicholls, MD, PhD discusses the robust efficacy and tolerability of zerlasiran for Lp(a) lowering, paving the way for Phase 3 development.
3 hours ago
Noaiseh discussed data from the DAHLIAS study linking, for the first time, clinical responses, with autoantibody levels.
8 hours ago
UCB has announced the FDA’s approval of bimekizumab, also known as Bimzelx, for patients with moderate-to-severe HS.
8 hours ago
In these guidelines compiled by the ACAAI, the AAAAI, and the AAOA, recommendations are provided to insurance companies for documentation needed for allergen immunotherapy.